Speaker: Nikhil Munshi

0:03:33

Using cell mass to determine response to treatment: A possible cure?

0:01:00

Future perspectives on CAR-T therapy for multiple myeloma

0:01:34

Using MRD to guide MM treatment

0:02:37

Insights into the genomics of multiple myeloma - new drug targets and when to do a genomic analysis

0:02:19

Novel avenues for MM treatment: CAR T-cells, venetoclax, induction & MRD

0:05:11

Phase I study of PHE885 CAR T-cell therapy in R/R multiple myeloma

0:02:02

Updated Phase I study results of PHE885 in patients with R/R multiple myeloma

0:02:16

What novel technologies are available for myeloma?

0:01:43

Proteasome inhibitors in Multiple Myeloma

0:01:27

Early results of PHE885, a novel BCMA-directed CAR-T therapy for the treatment of R/R MM

0:01:41

Results from DETERMINATION: RVd with or without ASCT

0:01:32

The interaction between bone marrow stromal cells and tumor cells as a potential target in WM

0:03:00

Impact of ide-cel and future directions

0:01:00

Multiple Myeloma: a disease that changes

0:01:54

Genome sequencing and transcription analysis: improving MM understanding

0:48:06

The Latest Insights on Immune Therapies in Myeloma | 2023 IMF Patient and Family Seminar

0:00:58

The evolving cancer cell

0:00:39

CAR-T, bispecifics and MRD: how is treatment for multiple myeloma evolving?

0:00:50

CAR-T in multiple myeloma: cilta-cel & ide-cel

0:02:31

How to treat high-risk mutated myeloma

0:02:42

HDAC8: a novel therapeutic target in multiple myeloma

0:02:25

New insight into the biology of multiple myeloma: from clonal evolution to new treatment options

0:03:38

Three key messages for MRD negativity in multiple myeloma

0:05:52

BCMA targeting agents in myeloma